What is Dynavax Technologies?
Founded in 1996 and headquartered in Emeryville, California, Dynavax Technologies Corporation operates at the intersection of innate and adaptive immunology. The company specializes in the development of novel vaccines and disease-modifying therapies that utilize TLR stimulation to modulate the human immune system. Its diverse portfolio includes candidates targeting various cancer indications, hepatitis B prevention, and asthma management. As a clinical-stage entity, Dynavax maintains a rigorous focus on translating complex immunological research into viable, scalable medical solutions, positioning itself as a critical innovator in the biotechnology ecosystem.
How much funding has Dynavax Technologies raised?
Dynavax Technologies has raised a total of $293.9M across 5 funding rounds:
Stock Offering
$45M
Stock Offering
$20.1M
Stock Offering
$43.9M
Stock Offering
$85.9M
Debt
$99M
Stock Issuance/Offering (2004): $45M, investors not publicly disclosed
Stock Issuance/Offering (2010): $20.1M, investors not publicly disclosed
Stock Issuance/Offering (2010): $43.9M, investors not publicly disclosed
Stock Issuance/Offering (2013): $85.9M, investors not publicly disclosed
Debt (2021): $99M backed by Coalition for Epidemic Preparedness Innovations
Key Investors in Dynavax Technologies
Coalition for Epidemic Preparedness Innovations
A global partnership launched to develop vaccines to stop future epidemics, focusing on accelerating the development of vaccines against emerging infectious diseases.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Dynavax Technologies?
Looking ahead, the infusion of capital from the recent financing round is expected to catalyze the advancement of Dynavax's core clinical assets. The company is likely to prioritize the expansion of its vaccine development initiatives and the progression of its oncology pipeline through late-stage clinical trials. By leveraging its established TLR platform, Dynavax aims to address significant unmet medical needs, potentially shifting the standard of care in its target therapeutic areas. Strategic resource allocation will be paramount as the firm transitions from research-heavy operations toward potential commercialization milestones, ensuring that its financial runway aligns with the demanding timelines of regulatory approval and market entry.
See full Dynavax Technologies company page
